stella
beta
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) — Stella
Recruiting
Back to Immune Thrombocytopenia trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality
View full record on ClinicalTrials.gov